- Home
- / Anhui Fengyuan Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Anhui Fengyuan Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥6.3
2024-10-29
Market Capitalization
¥2.9 B
2024-10-29
Revenue
¥4.2 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 3.1B | 3.2B | 3.4B | 3.9B | 4.1B | 4.2B |
| Cost of goods sold | 1.8B | 2.0B | 2.2B | 2.4B | 2.9B | 3.2B | 3.4B |
| Gross profit | 1.1B | 1.2B | 1.1B | 1.0B | 1.1B | 1.1B | 898.5M |
| Gross profit margin, % | 38.3% | 34.6% | 29.9% | 28.2% | 25.6% | 21.6% | |
| Operating expense total | 945.2M | 1.0B | 905.3M | 796.3M | 818.4M | 759.7M | 614.3M |
| Depreciation and amortization | 74.8M | 70.6M | 89.0M | 83.6M | 94.4M | 99.3M | 99.7M |
| EBITDA | 190.5M | 188.8M | 213.5M | 228.0M | 279.1M | 301.9M | 284.2M |
| EBITDA margin, % | 6.0% | 6.6% | 6.7% | 7.2% | 7.3% | 6.8% | |
| EBIT | 121.4M | 148.0M | 160.2M | 188.0M | 228.5M | 235.3M | 228.5M |
| EBIT margin, % | 4.7% | 5.0% | 5.5% | 5.9% | 5.7% | 5.5% | |
| Interest income | 4.1M | 3.9M | 3.7M | 3.1M | 5.4M | 8.7M | 2.2M |
| Interest expense | 31.0M | 37.1M | 39.5M | 38.6M | 32.9M | 33.9M | 30.4M |
| Pre tax profit | 93.1M | 119.9M | 138.1M | 149.7M | 202.3M | 214.9M | 208.7M |
| Income tax expense | 32.4M | 39.3M | 36.0M | 40.3M | 51.4M | 57.6M | 51.1M |
| Net Income | 60.7M | 80.6M | 102.1M | 109.5M | 150.9M | 157.3M | 157.7M |